The combination of BMS-986253 (a humanized IgG1 anti-IL-8 monoclonal antibody) and nivolumab has demonstrated safety and preliminary efficacy in patients with melanoma who have progressed on earlier anti-PD1 therapy (56), and has been shown to result in suppression of circulating IL-8 as well as intra-tumoral CD15+ neutrophils (57). Here, CXCL8 is linked to melanoma.